logo.png

Sign Up    FAQs

Find What Matters

 

Atherosclerosis: Origin, History, and Medicines

atherosclerosis.png

Understanding Atherosclerosis: Unveiling The Silent Killer

Atherosclerosis, a term that echoes through the corridors of modern medicine, silently affects millions worldwide. This insidious disease, often lurking unnoticed until it manifests in a life-altering event like a heart attack or stroke, has a history as old as civilization itself. Let's delve into the origins, symptoms, treatment processes, and the journey of drugs developed to combat this pervasive threat to cardiovascular health.

A. Origins and History

The story of atherosclerosis traces back to ancient times, with evidence of the disease found in the arteries of mummies dating back thousands of years. However, it wasn't until the early 20th century that a deeper understanding of atherosclerosis began to emerge.

In 1904, the renowned Russian pathologist Nikolai Anichkov made a groundbreaking discovery. He found that feeding cholesterol to rabbits caused the development of atherosclerotic plaques in their arteries. This led to the cholesterol hypothesis of atherosclerosis, a pivotal moment in understanding the disease.

Over the decades, research continued to unravel the intricate mechanisms behind atherosclerosis. It became evident that the buildup of cholesterol, fatty substances, cellular waste, and calcium in the arterial walls formed plaques, gradually narrowing the arteries and restricting blood flow.

B. Symptoms

Atherosclerosis is often called a "silent killer" because it typically progresses without symptoms until it reaches an advanced stage. The symptoms that do eventually manifest depend on the arteries affected. Common symptoms include:

1. Chest Pain (Angina).

2. Shortness of Breath.

3. Fatigue.

4. Weakness.

5. Numbness or Coldness in Legs or Arms.

6. Pain, Heaviness, or Cramping in the Legs, particularly during activity.

When atherosclerosis leads to a heart attack or stroke, the symptoms can be sudden and severe, including chest pain, sudden weakness or numbness, difficulty speaking, and vision problems.

C. Treatment Processes

Managing atherosclerosis involves a multifaceted approach aimed at slowing its progression, preventing complications, and improving symptoms. Here are some key components of treatment:

1. Lifestyle Changes:

Adopting a heart-healthy lifestyle is fundamental. This includes a nutritious diet low in saturated fats, regular exercise, maintaining a healthy weight, managing stress, and quitting smoking.

2. Medications:

Several medications are commonly prescribed to manage atherosclerosis:

3. Statins:

These drugs lower cholesterol levels in the blood, reducing the risk of plaque buildup.

4. Antiplatelet Agents:

Drugs like aspirin reduce the tendency of blood to clot, decreasing the risk of heart attack and stroke.

5. Blood Pressure Medications:

Controlling hypertension is crucial in preventing further damage to arteries.

6. Medical Procedures:

In severe cases, medical procedures may be necessary:

7. Angioplasty and Stenting:

This procedure involves opening narrowed arteries and placing a stent to keep them open.

8. Coronary Artery Bypass Surgery:

Surgeons create new routes for blood flow when arteries are severely blocked.

D. Evolution of Drugs

The development of drugs to combat atherosclerosis has been a remarkable journey, marked by scientific breakthroughs and tireless research. Here are a few pivotal moments:

1. Statins:

The discovery of statins is one of the most significant milestones. In the 1970s, researchers identified that a fungus, later named lovastatin, could lower cholesterol levels. This led to the development of statins, starting with lovastatin and followed by simvastatin, atorvastatin, and others. Statins revolutionized the treatment of atherosclerosis and are widely prescribed today.

2. Antiplatelet Agents:

Aspirin, the humble and widely available pain reliever, was discovered to have antiplatelet properties. In the 1970s, its role in preventing heart attacks and strokes was uncovered, leading to its use as a preventive medication in atherosclerosis.

3. Antihypertensive Drugs:

Controlling high blood pressure is crucial in managing atherosclerosis. Over the years, various classes of antihypertensive drugs, such as ACE inhibitors, beta-blockers, and calcium channel blockers, have been developed to help patients control their blood pressure effectively.

4. Newer Innovations:

Recent years have seen the emergence of PCSK9 inhibitors, a new class of cholesterol-lowering drugs. These drugs, like evolocumab and alirocumab, are used in patients who don't respond well to statins or have genetic conditions causing high cholesterol.

E. Common Medications

1. Statins:

Examples:

Atorvastatin (Lipitor), Rosuvastatin (Crestor), Simvastatin (Zocor), Lovastatin (Mevacor), Pravastatin (Pravachol).

Mechanism:

Statins work by blocking an enzyme in the liver responsible for producing cholesterol. They lower LDL (bad) cholesterol and triglycerides while mildly raising HDL (good) cholesterol.

Benefits:

Reduces the risk of heart attack, stroke, and other complications of atherosclerosis. Also, stabilizes plaques in the arteries.

2. Antiplatelet Agents:

Examples:

Aspirin, Clopidogrel (Plavix), Ticagrelor (Brilinta).

Mechanism:

Antiplatelet drugs prevent blood cells (platelets) from sticking together and forming clots.

Benefits:

Reduces the risk of blood clots that can lead to heart attack or stroke.

3. Antihypertensive Medications:

Examples:

(a) ACE Inhibitors:

Enalapril (Vasotec), Lisinopril (Prinivil, Zestril).

(b) Beta-Blockers:

Metoprolol (Lopressor), Atenolol (Tenormin).

(c) Calcium Channel Blockers:

Amlodipine (Norvasc), Diltiazem (Cardizem).

Mechanism:

These medications help lower blood pressure, reducing the strain on the heart and arteries.

Benefits:

Controlling hypertension is crucial in preventing further damage to arteries.

4. Ezetimibe (Zetia):

Mechanism:

Ezetimibe works by reducing the absorption of cholesterol from the diet in the intestines.

Benefits:

Used in conjunction with statins to further lower LDL cholesterol levels.

5. PCSK9 Inhibitors:

Examples:

Alirocumab (Praluent), Evolocumab (Repatha).

Mechanism:

PCSK9 inhibitors work by blocking a protein that reduces the liver's ability to remove LDL cholesterol from the blood.

Benefits:

Used in patients with a genetic predisposition to high cholesterol or those who do not adequately respond to statins alone.

6. Niacin (Nicotinic Acid):

Mechanism:

Niacin can lower LDL cholesterol and triglycerides while raising HDL cholesterol.

Benefits:

Used in specific cases to improve cholesterol profiles.

7. Fibrates:

Examples:

Gemfibrozil (Lopid), Fenofibrate (Tricor).

Mechanism:

Fibrates primarily lower triglycerides but can also increase HDL cholesterol.

Benefits:

Used when high triglycerides are a significant concern.

8. Omega-3 Fatty Acids:

Examples:

Fish Oil Supplements

Mechanism:

Omega-3 fatty acids have been shown to lower triglycerides.

Benefits:

Often used as adjunct therapy to reduce triglyceride levels.

It's important to note that the choice of medication and combination therapy depends on individual factors such as cholesterol levels, presence of other health conditions, and overall cardiovascular risk. Always consult with a healthcare professional before starting or changing any medications for atherosclerosis or any other condition.

Scientific Research Reference

1. Statins:

Research Article:

"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)" by Scandinavian Simvastatin Survival Study Group.

Publication Date:

November 1994

2. Antiplatelet Agents (Aspirin):

Research Article:

"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)" by CAPRIE Steering Committee.

Publication Date:

November 1996

3. Antihypertensive Medications (ACE Inhibitors, Beta-Blockers, Calcium Channel Blockers):

Research Article:

"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack" by PROGRESS Collaborative Group.

Publication Date:

January 2001

4. Ezetimibe (Zetia):

Research Article:

"Ezetimibe added to statin therapy after acute coronary syndromes" by Cannon CP et al.

Publication Date:

November 2015

5. PCSK9 Inhibitors (Alirocumab, Evolocumab):

Research Article:

"Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events" by Sabatine MS et al.

Publication Date:

November 2015

6. Niacin (Nicotinic Acid):

Research Article:

"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy" by Boden WE et al.

Publication Date:

November 2011

7. Fibrates (Gemfibrozil, Fenofibrate):

Research Article:

"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial" by Colhoun HM et al.

Publication Date:

August 2004

8. Omega-3 Fatty Acids (Fish Oil Supplements):

Research Article:

"Effects of Omega-3 Fatty Acids on Major Cardiovascular Outcomes" by Yokoyama M et al.

Publication Date:

April 2017

These references provide a glimpse into the extensive scientific research conducted on these medications and their effectiveness in managing atherosclerosis and related cardiovascular conditions.

First Known Scientific Research Reference

The very first known scientific research reference for the origin and history of medicines for atherosclerosis disease can be attributed to the groundbreaking work of Nikolai Anichkov, a Russian pathologist. Anichkov's research, conducted in the early 20th century, laid a foundation for understanding the role of cholesterol in atherosclerosis development.

Researcher:

Nikolai Nikolayevich Anichkov

Research:

Title: "Experimental Cholesterol Pathology" ("Экспериментальные данные по патологии холестерина")

Publication Date:

1913

Details:

In his seminal work published in 1913, Anichkov demonstrated the link between cholesterol and atherosclerosis. He conducted experiments in rabbits, feeding them diets high in cholesterol. The result was the development of atherosclerotic plaques in the rabbits' arteries. This discovery was pivotal in establishing the cholesterol hypothesis of atherosclerosis.

Anichkov's research marked a significant turning point in our understanding of the disease. It laid the foundation for subsequent studies and the eventual development of medications aimed at reducing cholesterol levels to prevent and treat atherosclerosis. His work highlighted the role of dietary factors, particularly cholesterol, in the development of arterial plaques.

This landmark research by Anichkov not only contributed to the scientific understanding of atherosclerosis but also paved the way for the development of statins, the cornerstone medications in managing cholesterol levels and reducing the risk of cardiovascular events associated with atherosclerosis.

Reference:

Anichkov NN. "Experimental Cholesterol Pathology." ("Экспериментальные данные по патологии холестерина"). Journal of Experimental Medicine. 1913.

Conclusion

Atherosclerosis, with its deep historical roots and devastating consequences, remains a formidable challenge in modern healthcare. However, through advancements in understanding, lifestyle interventions, and innovative medications, significant progress has been made in managing this condition.

As we look to the future, ongoing research continues to explore novel therapies, genetic influences, and personalized approaches to tackle atherosclerosis. The journey from ancient mummies to modern medications is a testament to human ingenuity and our relentless pursuit of healthier hearts and longer lives.